RxDoctor Payments Data

Brandon Barthel, MD

Endocrinology, Diabetes & Metabolism · Kansas City, MONPI 1235454554

Payments from drug & device makers

$849in general payments, 2019–2025

Across 17 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$286
  • Sanofi-aventis U.S. LLC$147
  • Amgen$121
  • Mannkind Corporation$97
  • Novo Nordisk$76
  • Zealand Pharma US, Inc.$37
  • plus $86 from 3 others

What the payments were for

  • Food & beverage$79093%
  • Gifts$597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849 in reported general payments places this provider in the 40th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$16,703
Medicare patients
79
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide160$216,627
JardianceEmpagliflozin47$84,834
TrulicityDulaglutide72$78,320
MounjaroTirzepatide33$46,563
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$34,657
FarxigaDapagliflozin Propanediol38$34,120
JanuviaSitagliptin Phosphate18$17,247
Novolog FlexpenInsulin Aspart44$14,041
Tresiba Flextouch U-100Insulin Degludec14$10,312
Cequr SimplicityBolus Insulin Pump, 200 Unit12$10,077
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$9,292
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,042
Humalog Kwikpen U-100Insulin Lispro27$7,379
NovologInsulin Aspart26$4,495
HumalogInsulin Lispro16$3,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$76$221,122186 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$26$129,443138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →